ArticleFrontiers in oncology2025

Early C-reactive protein reduction predicts survival in real-world extensive-stage small cell lung cancer treated with first-line adebrelimab-based immunotherapy.

Jian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.